Clinical Trials Browser

INDUSTRY × Acromegaly × Clear all

Gastro-enteropancreatic neuroendocrine tumor, Acromegaly

NCT06253897 2024-12-24

BackSOM

Completed

20 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Acromegaly

NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

Phase 4 Completed

337 enrolled 8 charts

DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

NCT00446082 2020-12-21

Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease

Phase 1 Completed

85 enrolled

Endocrine

Acromegaly, Carcinoid Tumor

NCT02354508 2019-12-10

Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues

Phase 3 Completed

123 enrolled 27 charts

Endocrine

Acromegaly, Gigantism, Growth Disorders, Pituitary Neoplasms

NCT01673646 2019-09-16

Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism

Phase 2 Completed

33 enrolled 24 charts

Endocrine

Acromegaly, Gigantism, Growth Disorders, Pituitary Neoplasms

NCT01840449 2019-01-14

SOPRANo

Completed

156 enrolled

EndocrineNET

Acromegaly, Neuroendocrine Tumors

NCT01137682 2018-04-05

PAOLA

Phase 3 Completed

198 enrolled 17 charts

Endocrine

Acromegaly, Pituitary Neoplasms

NCT02299089 2017-12-15

Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)

Phase 2 Completed

12 enrolled 18 charts

EndocrineNET

Acromegaly, Neuroendocrine Tumors, Serotonin Syndrome

NCT00376064 2017-03-06

Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

Phase 4 Completed

20 enrolled

CNSEndocrine

Acromegaly, Brain Neoplasms, Pituitary Neoplasms

NCT00171886 2017-02-24

Octreotide Efficacy and Safety in First-line Acromegalic Patients

Phase 4 Completed

20 enrolled

Acromegaly

Clinical Trials

OXTEND-01

BackSOM

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease

Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues

Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism

SOPRANo

PAOLA

Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)

Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

Octreotide Efficacy and Safety in First-line Acromegalic Patients